Immunocore 2026 EPS Loss Estimates Narrow to $0.90, Shares Up 1.5%
In the past 60 days, estimates for Immunocore’s 2026 loss per share narrowed from $0.97 to $0.90, while its shares have gained 1.5% over the past six months. The company beat consensus estimates in three of the trailing four quarters, delivering an average earnings surprise of 53.96%.
1. 2026 EPS Estimate Revision
Over the past 60 days, analysts have reduced Immunocore’s projected 2026 loss per share from $0.97 to $0.90, reflecting tighter cost controls and anticipated revenue improvements in its immuno-oncology programs.
2. Stock Performance
Immunocore shares have risen 1.5% over the past six months, tracking investor confidence in the company’s narrowing loss outlook despite a challenging biotech sector.
3. Historical Earnings Surprise
The company has exceeded consensus estimates in three of its last four quarterly reports, registering an average earnings surprise of 53.96%, which underscores the variability in its financial results and analysts’ forecasts.